The ACMS recommended that Growth Hormone Releasing Hormones (GHRHs), Growth Hormone Secretagogues (GHSs), Growth Hormone Releasing Peptides (GHRPs) as well as new individual substance entries for CJC-1295, ipamorelin, pralmorelin (Growth Hormone Releasing Peptide-2), Growth Hormone Releasing Peptide-6, hexarelin and AOD-9604 be included in Schedule 4.
As simple and basic as it is, eating less calories is much harder in practice than it sounds. Ask anyone who has ever gone on a diet before! Everyone knows if you want to lose weight, you need to eat less. It’s the first step of any legitimate diet and fitness program, but how much less, and what to eat remains a mystery to many dieters. Or, the results don’t come quickly enough and the dieter gives up before real results are experienced.
Ipamorelin is a man-made peptide that is part of the growth hormone family. Rated as one of the safest in the peptide industry, it has strong growth hormone releasing properties. From this, it is a huge winner with athletes and bodybuilders. This is because it builds muscle and keeps weight down quickly. It works by sending signals to the pituitary gland at the base of the brain and adjusts and controls various body functions through the endocrine system. It binds certain receptors inside cells. This allows cells to respond and change, encouraging growth and regulation of hormones. Ipamorelin can help with:
Figure 2. A, Concentrations of plasma mature BNP levels at baseline and at 40, 80, 120, and 180 minutes after the start of saline infusion. Solid line with squares represents pre‐bypass surgery subjects and dotted line with triangles represents post‐bypass surgery subjects. B, Concentrations of plasma Nt‐proBNP levels at baseline and at 40, 80, 120, and 180 minutes after the start of saline infusion. Solid line with squares represents pre‐bypass surgery subjects and dotted line with triangles represents post‐bypass surgery subjects. BNP indicates B‐type natriuretic peptide; Nt‐proBNP, N‐terminal pro‐BNP.
Time line of collagenase, saline, HA and AOD9604 injection. Collagenase (0.25 mg) was injected in right knee twice on day 1 and 4, respectively. Normal saline 0.6 ml (group 1), HA 6 mg (group 2), AOD9604 0.25 mg (group 3), and AOD9604 0.25mg with HA 6 mg (group 4) were injected in the right knee at 4 weeks after the first collagenase injection. All rabbits were euthanized by CO inhalation at 4 weeks after injection of 4 different solutions.
AOD9604 and hGH appear to act in a similar manner to induce their effects on body weight regulation and adipose tissue mass in vivo. However, in vitro studies have demonstrated a number of differences suggesting that the two compounds operate via unique signaling pathways to control the regulation of theβ 3-AR. These studies suggested that AOD9604 had no interaction with the β3-AR or hGH receptors (11).
First, when buying them, peptides are stored in the refrigerator. It is necessary to wash your hands before administering every preparation. Peptides are mixed with sterilized water. After taking 2 to 1ml sterilized water with a syringe, you should let it run down the wall of the peptide vial. Let it rest for ten minutes then mix gently. It is important not to stir the solution.
Note: If you are a person concerned about loss of muscle mass, you can consume a small amount of protein every 2-3 hours (amino acid tablets such as EAA and BCAA are good for this purpose and can be purchased from any health food shop or ordered online). However there is little reason to be concerned about muscle loss because when fat is available for energy, such as following HGH Frag 176-191 injections, protein and therefore muscle mass are spared.
CJC-1295 is also known by the names of Modified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC (DAC stands for Drug Affinity Complex) and also by its chemical name tetrasubstituted GRF (1-29). This variety of names makes it difficult for the average consumer to select or even research upon this compound. Since some manufacturers list all of its names and others list only one, it also becomes very confusing. However, there is a reason for this wide variety of names.
LR3 would be great for fatloss. I would use that solo (not with cjcdac or gh)... obviously if you have any clen, t3, eca etc then you could add them in. I have limited experience with lr3 so can't fully comment from my own research. But from what I observed on Bane it is great for fatloss... anything that raises igf-1 should be. But the results from the cjc-dac were superior in every way during my research.
The amazing effects of HCG on the hypothalamus were discovered by Dr. Albert T. W. Simeons in 1954, who observed that malnourished women tend to give birth to healthy babies with normal birth weights. Dr. Simeons concluded that women are able to do this because the HCG hormone that their bodies naturally produced during pregnancy helped their bodies to metabolise subcutaneous fat. hCG released by the embryo also helps women with weight redistribution (helps prevent uneven deposits of weight on thighs, abdomen, hips etc) and therefore women concerned with hormonal weight gain are ideal candidates for this diet.
Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice. One mechanism by which this may occur is through an interaction with theβ -adrenergic pathway, particularly with theβ 3-adrenergic receptors (β3-AR). Here we describe how hGH and AOD9604 can reduce body weight and body fat in obese mice following 14 d of chronic ip administration. These results correlate with increases in the level of expression ofβ 3-AR RNA, the major lipolytic receptor found in fat cells. Importantly, both hGH and AOD9604 are capable of increasing the repressed levels of β3-AR RNA in obese mice to levels comparable with those in lean mice. The importance ofβ 3-AR was verified when long-term treatment with hGH and AOD9604 in β3-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice. However, in an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in theβ 3-AR knock-out mice. In conclusion, this study demonstrates that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the β3-AR although both compounds increase β3-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.

After the commencement of active treatment, 78.7% of subjects experienced at least one AE, with the incidence ranging from 75.6% to 83.2% across all treatment groups (83.2% placebo group; 75.6% 0.25 mg AOD9604 group). There was a high incidence of infections and infestations (46.8%, mainly nasopharyngitis, 17.1%), nervous system disorders (30.1%, mainly headache, 25.9%), musculo-skeletal and connective tissue disorders (25.5%, mainly back pain, 8.2%), and gastrointestinal disorders (22.9%, mainly diarrhea, 7.8%). Although the percentage of subjects experiencing AEs in these body systems is higher than in the run-in period there was no obvious pattern with respect to treatment received, suggesting that the increase was likely due to the longer period of assessment in the active treatment phase.


The human growth hormone (hGH) is a 191-amino acid long, single-chain polypeptide secreted by the pituitary gland under the regulation of the hypothalamus. It regulates a variety of biological processes in various tissues. When binding to the hGH-receptor it activates one of various signaling cascades, depending on the tissue. In the liver hGH induces the secretion of Insulin-Like Growth Factor-1 (IGF-1). IGF-1 can stimulate growth in almost every tissue in the body, including skeletal muscle, cartilage, bone, liver, kidney, nerves etc. [1].


The literature presented in this paper argues that our limited ability to maintain energy balance in a weight-reduced state is the product of our difficulty in compensating for the weight loss-induced reduction in total energy expenditure. The end result, translated into the overwhelming complexity of preserving long-term weight loss, is presented as being a consequence of compromised appetite control. Given the present-day food landscape and the resultant susceptibility to passive overconsumption, the focus of this review will be on the peripheral ("bottom-up") signals (leptin, PYY, ghrelin, and GLP-1) and the evidence highlighting their influence on feeding behaviour. As we continue studying paradigms of body mass reduction, specifically the data emerging from patients of bariatric surgery, it is becoming clearer that counter-regulatory adaptations, possibly through down-(leptin, PYY, and GLP-1) or upregulation (ghrelin) of peptides, have an impact on energy balance. In itself, food deprivation influences some of the peptides that ultimately provide the physiological input for the overt expression of feeding behaviour; these peripheral adaptations are expected to serve as feeding cues--cues that, in the end, can serve to compromise the maintenance of energy balance. In a potentially novel intervention to increase compliance to long-term reductions in energy intake, it is proposed that manipulating the pattern of food intake to favourably alter the profile of gastrointestinal peptides would lead to better dietary control.

At the time that decision was made, paracetamol/caffeine combinations were available over-the-counter in over 50 other countries and had been exempt from scheduling in a number of major markets that are similar to Australia in terms of population type and regulatory status. Experience with the unscheduled sale of this product was extensive: UK 19 years, Ireland 12 years and New Zealand for 7 years. However, the Committee determined not to consider paracetamol combined with caffeine for exemption from scheduling until market experience had been gained with use as a Schedule 2 product in Australia.


The test substance was either administered intravenously (studies METAOD001 and METAOD002) or as a capsule/tablet. The hexadecapeptide AOD9604 was produced under cGMP conditions by PolyPeptide Laboratories (Torrance, CA, USA). For studies 1 and 2, the product was supplied in a lyophilized form and reconstituted before usage with the designated volume of sterile water for intravenous injection. The capsules/tablets were manufactured using a common excipient mix (Capsules: Mannitol, PEG3350 (in studies METAOD003, METAOD004 and METAOD005)); or Tablets: L-Arginine Free Base, Microcrystalline Cellulose, Fumed silica, Magnesium Stearate (in study METAOD006)).
Male New Zealand white rabbits (n=32; aged 12 weeks) were used in the experiments. Animals were housed in separate metal cages at a temperature of 23°C±2°C and relative humidity of 45%±10%. The animals were allowed free access to tap water and were fed a commercial rabbit diet. Animal experiments were performed in accordance with internationally accredited guidelines and approved by laboratory’s Institutional Animal Care and Use Committee.
In June 2011 the Advisory Committee on Medicines Scheduling was referred a proposal by the delegate to consider up-scheduling of five (5) then unscheduled substances contained in cold and cough preparations into Schedule 2. One of these substances was phenylephrine and many public submissions received rejected this proposal on the grounds of the paracetamol/phenylephrine exemptions in the Schedule 2 entry. The committee made similar comments and the delegate agreed that the current exempt from scheduling status of phenylephrine was appropriate.
To really test the health benefits of drinking collagen peptides, I vowed to take it every day for two weeks. I opted for Vital Proteins Unflavored Grass-Fed Collagen Peptides in the blue tub. I got the 20-ounce tub and a box of the stick packs, which were perfect for when I went out of town. I stuck with one scoop from the tub for 35 calories, 9 grams of protein, and 10 grams of collagen (this was the same serving size in the stick packs).
There were concerns regarding the number of contraindications and precautions and whether consumers would be able to interpret these appropriately without a requirement for pharmacist advice. There were concerns regarding gastro-intestinal, renal and other adverse effects related to the potential interactions of ibuprofen and paracetamol. Also raised were concerns regarding the potential for paracetamol overdose.
ASADA gave advice to the ACC, and perhaps Essendon, that AOD-9604 was not banned under the S2 category. Given the expectation that AOD-9604 would not be anabolic because it lacked the ''anabolic region'' of HGH, it is perhaps understandable that ASADA did not classify it under S2 in 2011 and 2012, although its close structural relationship to the banned HGH should have been sufficient to include it on the banned list.
The discovery of the role of Tβ4 in the process of immune regulation has lead to its use as a valuable therapeutic agent. Tβ4 has been used in the treatment of HIV, AIDS, Influenza, colds, and various infections. It has been utilized in the management of various inflammatory conditions, as well as part of treatment following heart attack due to its cardio and neuroprotective effects.
Background: The human growth hormone (hGH) has fat loss properties making it a potential candidate to treat obesity. AOD 9604 is a peptide fragment of the C-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity of hGH, without its negative effects. In this paper the safety data of AOD 9604 obtained in clinical trials are summarized.

Example 1 - Night Time Injection (recommended) ◦Ensure you do not eat or drink anything containing calories within three (3) hours of going to bed (with the exception of water, diet sodas, coffee/tea with artificial sweeteners). ◦Take your HGH Frag 176-191 injection just before getting into bed and your body will therefore be burning stored fat for the duration of your sleep. ◦If possible, do some cardio first thing in the morning and wait as long as possible before having breakfast to allow the fat burning to continue throughout the morning/day.


The original GRF (1-29) has a half-life of about 30 minutes. Half-life means the time within which half of the hormone administered will be destroyed within the body. This short half-life is due to the fact that the compound is highly unstable and breaks down soon. To increase its stability and to make it last longer, it was modified by adding 4 amino acids in its structure. This gave it the name Modified GRF (1-29) or Mod GRF 1-29. It was originally invented by DatBtrue. The portion of the molecule that actually stimulates the growth hormone secretion is found in the chain of 29 amino acids, so it is named GRF (1-29). This chemical also produces slow-wave sleep.
The interim decision was to include in Schedule 4 and in Appendix D Item 5 Growth Hormone Releasing Hormones (GHRHs), Growth Hormone Secretagogues (GHSs), Growth Hormone Releasing Peptides (GHRPs) as well as new individual substance entries for CJC-1295, ipamorelin, pralmorelin (Growth Hormone Releasing Peptide-2), Growth Hormone Releasing Peptide-6, hexarelin and AOD-9604.
Example 2 - Morning Injection ◦Wake up and inject your HGH Frag 176-191 (250mcg to 500mcg is a good dosage depending on your budget). ◦Wait as long as possible before having your first meal (the longer you wait the more fat you will burn). ◦When you do eat, try to make the meal high protein, low fat and low carbohydrate (example meat and salad/vegetables). ◦If possible, try to do some cardio in the hours after your injection to increase the fat burning effect.
Many patients use Ipamorelin short term (3-6 months) for fat loss benefits and overall improvements in body composition. Ipamorelin increases fat metabolism, so when age starts to become a factor in a person’s ability to lose weight, this peptide can create a more efficient and sometimes faster process. Patients that are also physically active tend to notice even faster benefits while using Ipamorelin, as it aids recovery from workouts and allows for faster progression and typically more fat loss. Once a patient’s desired weight has been achieved, Ipamorelin use can be discontinued, and weight maintenance can be achieved through diet and lifestyle changes.
Hexarelin: Part of a family of drugs called growth hormone-releasing peptides (GHRP; commonly shortened in media to “peptides”) Hexarelin increases the body’s production of its own human growth hormone, and in so doing may help increase muscle mass and strength. The potential adverse effects of repeated doses of peptides may include various hormonal imbalances in the body. Hexarelin is banned by WADA. –– Benjamin Koh
The literature presented in this paper argues that our limited ability to maintain energy balance in a weight-reduced state is the product of our difficulty in compensating for the weight loss-induced reduction in total energy expenditure. The end result, translated into the overwhelming complexity of preserving long-term weight loss, is presented as being a consequence of compromised appetite control. Given the present-day food landscape and the resultant susceptibility to passive overconsumption, the focus of this review will be on the peripheral ("bottom-up") signals (leptin, PYY, ghrelin, and GLP-1) and the evidence highlighting their influence on feeding behaviour. As we continue studying paradigms of body mass reduction, specifically the data emerging from patients of bariatric surgery, it is becoming clearer that counter-regulatory adaptations, possibly through down-(leptin, PYY, and GLP-1) or upregulation (ghrelin) of peptides, have an impact on energy balance. In itself, food deprivation influences some of the peptides that ultimately provide the physiological input for the overt expression of feeding behaviour; these peripheral adaptations are expected to serve as feeding cues--cues that, in the end, can serve to compromise the maintenance of energy balance. In a potentially novel intervention to increase compliance to long-term reductions in energy intake, it is proposed that manipulating the pattern of food intake to favourably alter the profile of gastrointestinal peptides would lead to better dietary control.

†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Use only as directed. Consult your healthcare provider before using supplements or providing supplements to children under the age of 18. The information provided herein is intended for your general knowledge only and is not intended to be, nor is it, medical advice or a substitute for medical advice. If you have or suspect you have, a specific medical condition or disease, please consult your healthcare provider.
Tissues from ob/ob and lean mice were cut into 100-mg pieces and homogenized with 1 ml TRIzol (Life Technologies, Inc., Grand Island, NY) using a PolyTron homogenizer (Kinematica, Lausanne, Switzerland). The samples were incubated for 5 min at room temperature to permit the complete extraction of the RNA from the tissues. An aliquot of 0.2 ml chloroform was added to each milliliter of TRIzol. The method of RNA extraction was as described by the manufacturer (Life Technologies, Inc.). The final RNA pellet was air dried for 5–10 min and then resuspended in 20 μl ddH20. RNA was quantitated spectrophotometrically using the A260/280 ratio.
Ironically, it only appears that the version of IGF-1 produced in your own muscle has any true anabolic effects. But nonetheless, many folks who’ve used IGF-1 claim to have experienced significant anabolic effects of injections. However, the only evidence for such anabolic effects have been shown in people who are already clinically deficient in IGF-1.
Whilst not illegal to buy AOD9604 in Australia, AOD9604 does not have approval by the TGA, which means it is not allowed to be sold on the basis of it having any pharmaceutical or performance enhancing benefits. It has not been approved by any pharmaceutical authority worldwide, except for the previously mentioned "Generally Regarded As Safe" designation by the FDA. AOD9604 is currently classed by the World Anti Doping Agency (WADA) as a non-approved substance, which means it is not legal for use by athletes in competition. WADA policy is to ban all substances that are suspected of being performance-enhancing, even in the absence of clinical proof (1,2).
In the 80 years, scientists have searched different peptides and more particularly GHRH to discern what part was necessary to stimulate the pituitary response. Then in testing Sermorelin as a tool for the process of anti-agingthey found that it was the famous 1-29 chain that was responsible for stimulating the endocrine gland in question. Similarly, many studies have shown that this peptide was similar to GHRH and very well tolerated by the body.

In vitro and in vivo investigations revealed a specific region within the hormone molecule that is responsible for the molecular events associated with lipid metabolism [18, 24, 25]. AOD9604 is a peptide fragment of the C-terminus or lipolytic domain of hGH (hGH177-191), with an additional tyrosine residue at the N-terminal end for stabilization. In vitro and in vivo experiments have shown similar effects of AOD9604 and hGH on lipid metabolism when chronically applied to mice [20, 21]. Interestingly, AOD9604 mimics the effect of hGH on lipid metabolism, without having growth promoting or pro-diabetic effects. The safety and tolerability of AOD9604 has been studied in the human clinical trials described in this paper.
Paracetamol/caffeine formulations have a long-established safety and efficacy profile over 25 years of use as an open-sale medicine in major markets around the world. The paracetamol/caffeine combination analgesic was registered as a schedule 2 product in Australia and has been marketed since 2010. Since that time no new significant issues or potential risks have been reported.

Experimental animals were anesthetized with an intramuscular injection of xylazine (Rompun®; Bayer Co., Seoul, Korea) at a dose of 1.9 mg/kg and ketamine (Ketar®; Yuhan Co., Seoul, Korea) at a dose of 46 mg/kg. The right knee joints of all rabbits were shaved and sterilized. Then, 2 mg of collagenase type II from Clostridium histolyticum (Sigma Co., St. Louis, MO, USA) was prepared for intra-articular injection. Collagenase was dissolved in a sterile phosphate buffered saline (pH 7.4) and filtered with a 0.22-μm membrane. The solution was slowly injected into the right knee joint using ultrasound guidance. The same injection was repeated 3 days after the first injection, as previously reported (Figure 1) [8].
The ACMS recommended that Growth Hormone Releasing Hormones (GHRHs), Growth Hormone Secretagogues (GHSs), Growth Hormone Releasing Peptides (GHRPs) as well as new individual substance entries for CJC-1295, ipamorelin, pralmorelin (Growth Hormone Releasing Peptide-2), Growth Hormone Releasing Peptide-6, hexarelin and AOD-9604 be included in Schedule 4.
As it is not yet approved for use in this country (or any other), it should always have been considered banned under the S0 category, which states that any pharmacological substance that is not addressed by any of the subsequent sections of the Prohibited List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited.

You can add CJC-1295 DAC at 2mg once per week (or 300mcg each day along with your HGH Frag 176-191 injections - they can be mixed in the same syringe without any issues). You should take a break from CJC-1295 DAC every few months to give your pituitary gland a rest at which time you can continue to use HGH Frag 176-191 on its own, or you can substitute the CJC-1295 DAC with the short acting Modified GRF 1-29 at 100-300mcg per day (split into injections of 100mcg).
Peptide therapy, or the use of specific peptides in treatment, has gained great popularity in recent years. This is due largely to the fact that these peptides are highly specific (i.e., only do what you want them to do) while also being well-tolerated and safe. As of January 2015, there were over 60 US FDA-approved peptide medications, 140 peptide drugs being evaluated in clinical trials, and 500 in pre-clinical development.
Finally, the hexadecapeptide AOD9604 did not induce allergenic reactions when consumed over 24 weeks. Blood of patients was analyzed for the presence of anti-AOD9604 antibody formation at various times and at the end of the studies (latest time point after 24 weeks). In none of the performed studies, at no time, were anti-AOD9604 antibodies detected in serum collected from any subjects in any treatment group.
Managing your weight is a hard task no matter your age. But as we age there are extenuating factors that make weight loss even harder. Lifestyle factors, having a desk job, less physical activity, hormone changes e.g. insulin sensitivity or sleep deficiency. While exercise and healthy eating are vital for weight loss, sometimes that’s easier said than done! That’s where we come in. You set the Resolution and we find you the Solution!

To obtain the best results from a fat loss program, and the most amount of fat loss from your peptide supplementation, you should be following a diet which is high in protein, moderate in healthy fats and low in carbohydrates, and be physically active. At the very least you should be doing some high-intensity lifting a couple of times a week alongside the implementation of cardio. You should also have your hormone levels balanced to optimise your metabolism.
You're the only person around here who is big-noting yourself with facts and then made a complete fool of yourself. I don't claim to be a science expert. I can freely admit I was ignorant and confused by Essendon fans saying this wasn't a PED. So I did a quick google search, read a few things about AOD9604 and posted it here. Not sure what your deal is.
As simple and basic as it is, eating less calories is much harder in practice than it sounds. Ask anyone who has ever gone on a diet before! Everyone knows if you want to lose weight, you need to eat less. It’s the first step of any legitimate diet and fitness program, but how much less, and what to eat remains a mystery to many dieters. Or, the results don’t come quickly enough and the dieter gives up before real results are experienced.
The Vital Proteins Collagen Peptides that I used claimed that it could dissolve in hot or cold liquids. However, I found it dissolved much easier when I poured some into hot tea or blended it into a smoothie. For the majority of the two weeks, I put my collagen peptides in my morning iced coffee. Instead of dissolving nicely, however, it ended up clumping into gelatinous pieces throughout my coffee. Although the peptides eventually dissolved with frequent stirring, I sometimes ended up slurping up chunks of the peptides.

I stopped the colostrum and my ” symptoms ” subsided, seems I have a moderately enlarged prostate which doesn’t run in my family on either side, my question is could the colostrum possibly cause the prostate to enlarge due to the igf-1 at a certain age,? due to a possible decline in testosterone, or could the benefits of colostrum outweigh the prostate issue?
When it comes to losing weight, no matter how little amount, it’s an uphill struggle…all the way! Using peptides correctly will provide surprisingly good results if the user can also put in some effort from the very start. Just by reducing your food and calorie drinks along with some daily exercise will soon reward you with a noticeable decrease in weight and fat loss.
Three of the submissions did not support the proposal highlighting the impact the change in scheduling would have on product currently on the market, industry, pharmacists and consumers. Two submissions noted that there has not been a history of concern with this combination of substances. One submission, referring to the NEJM article, believed that a lack of information about the study means that it cannot be relied upon as there is not a meaningful assessment of the results.
A total of 97 AEs were reported by 17/17 subjects during this study. Most of them were of mild or moderate in intensity, with the exception of two SAEs, one of which (diarrhoea) was deemed “possibly related” to study treatment (54 mg AOD9604) and one (bronchial pneumonia) deemed to be “unrelated” to the study treatment (54 mg AOD9604). The most common adverse event reported was mild or moderate headache followed by events related to the digestive system, specifically diarrhea, flatulence, increased appetite and nausea. There was no observable trend between the AOD9604 groups or the placebo with respect to the incidence. The only event deemed definitely related to the treatment was taste perversion occurring 10 minutes following dose administration of the placebo.

There are different things you have to consider when wanting to purchase peptides on the web. In the event that you would prefer not to squander your time and cash and hazard your life to get low quality peptides, dependably settle with the most solid and legitimate peptide provider as this can have a gigantic effect. In the event that despite everything you can’t locate a decent provider of first rate quality peptides, you can request your other’s proposals. You may likewise look at PEPTIDE CLINICS in the event that you need.

×